HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented… read more.
Nurix Therapeutics announced updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk… read more.
Most breast cancers are worsened by estrogens. To combat the recurrence of these cancers, clinicians treat patients with inhibitors for estrogen production, like letrozole. But many patients do not adhere to this treatment due to negative side effects. Preclinical work in… read more.
AbbVie announced that the FDA has approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options…. read more.
Pfizer announced detailed results from the pivotal Phase 3 TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway… read more.
Eli Lilly and Company announced positive topline results from the Phase III LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary… read more.
AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple… read more.
Eben Rosenthal, MD, the Barry and Amy Baker Professor and Chair of the Department of Otolaryngology-Head and Neck Surgery at Vanderbilt Health, is the senior author of the… read more.
Amneal Pharmaceuticals announced that the FDA has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. The product is eligible for Competitive Generic… read more.
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over… read more.
The Lancet Oncology Commission warns the shortfall, driven by rising cancer rates and workforce gaps, will place significant strain on health systems worldwide, with the largest shortages expected in nursing and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
